Back to News
Oct 9, 2025 12:00 PM

Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion

Novo Nordisk A/S (NYSE:NVO) agreed on Thursday to acquire Akero Therapeutics, Inc. (NASDAQ:AKRO) focused on metabolic diseases.

Transaction terms

Novo Nordisk will pay $54 per share in cash (or an aggregated value of $4.7 billion) at closing.

In addition, Akero shareholders will receive a non-transferable CVR entitling holders to a potential additional payment of $6 per share in cash (or an aggregated value of $0.5 billion) upon U.S. regulatory approval of EFX for the treatment of compensated cirrhosis due to MASH.

Strategic And Portfolio Fit

The acquisition reflects Novo Nordisk's long-term strategy to develop innovative and differentiated medicines for diabetes, obesity and associated comorbidities.

Akero's fibroblast growth factor 21 (FGF21) analog efruxifermin ...